Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...
pharmaphorum3d
After FDA no, Regeneron gets yes from EU on odronextamab
Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US. Ordspono (odronextamab) has been ...
Forbes5d
Inside The New York City Bar Where Water Is A Key Cocktail Ingredient
At New York City's Tokyo Record Bar and Listening Room, water is an intentionally curated ingredient ... [+] for highballs and Japanese twists on classic cocktails. Yana Volfson, the beverage ...
pharmaphorum6d
GSK and Vir expand COVID-19 antibody trial after Trump's treatment with Regeneron's rival
Antibody treatments for COVID-19 are currently in the spotlight after it emerged that president Donald Trump received treatment with a rival cocktail from Regeneron. The Regeneron therapy is still ...
Fox Business4d
Food and Drinks
Starbucks is getting into the Valentine’s Day spirit through limited-time drinks. It is also introducing two new Refreshers and a Midnight Drink for a limited time. The broader impact of ...